Have you assessed how the international operations of IQVIA Holdings (IQV Quick QuoteIQV - Free Report) performed in the quarter ended September 2025? For this clinical testing company, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects.

In the current era of a tightly interconnected global economy, the proficiency of a company to penetrate international markets significantly influences its financial health and trajectory of growth. For investors, the key is to grasp how reliant a company is on overseas markets, as this provides insights into the durability of its earnings, its ability to exploit different economic cycles, and its overall growth capabilities.

Being present in foreign markets serves as protection against local economic declines and helps benefit from more rapidly expanding economies. Yet, such expansion also introduces challenges related to currency fluctuations, geopolitical uncertainties and varied market behaviors.

Upon examining IQV's recent quarterly performance, we noticed several interesting patterns in the revenue generated from its international segments, which are commonly analyzed and observed by Wall Street experts.

The company's total revenue for the quarter amounted to $4.1 billion, marking an increase of 5.2% from the year-ago quarter. We will next turn our attention to dissecting IQV's international revenue to get a clearer picture of how significant its operations are outside its main base.

A Closer Look at IQV's Revenue Streams Abroad

Of the total revenue, $1.3 billion came from Europe and Africa during the last fiscal quarter, accounting for 31.6%. This represented a surprise of -0.44% as analysts had expected the region to contribute $1.3 billion to the total revenue. In comparison, the region contributed $1.24 billion, or 30.9%, and $1.29 billion, or 33%, to total revenue in the previous and year-ago quarters, respectively.

Asia-Pacific accounted for 21.2% of the company's total revenue during the quarter, translating to $870 million. Revenues from this region represented a surprise of +4.87%, with Wall Street analysts collectively expecting $829.61 million. When compared to the preceding quarter and the same quarter in the previous year, Asia-Pacific contributed $841 million (20.9%) and $771 million (19.8%) to the total revenue, respectively.

International Market Revenue Projections

Wall Street analysts expect IQVIA to report a total revenue of $4.25 billion in the current fiscal quarter, which suggests an increase of 7.4% from the prior-year quarter. Revenue shares from Europe and Africa and Asia-Pacific are predicted to be 31.8%, and 20.5%, corresponding to amounts of $1.35 billion, and $872.54 million, respectively.

For the full year, a total revenue of $16.18 billion is expected for the company, reflecting an increase of 5.1% from the year before. The revenues from Europe and Africa and Asia-Pacific are expected to make up 31.6%, and 20.6% of this total, corresponding to $5.12 billion, and $3.34 billion, respectively.

Concluding Remarks

Relying on global markets for revenues presents both prospects and challenges for IQVIA. Therefore, scrutinizing its international revenue trends is key to effectively forecasting the company's future outlook.

In an environment where global interconnections and geopolitical skirmishes are intensifying, Wall Street analysts keep a keen eye on these trends, particularly for firms with overseas operations, to adjust their earnings predictions. Moreover, a range of other aspects, including how a company fares in its home country, significantly affects these projections.

Emphasizing a company's shifting earnings prospects is a key aspect of our approach at Zacks, especially since research has proven its substantial influence on a stock's price in the short run. This correlation is positively aligned, meaning that improved earnings projections tend to boost the stock's price.

With an impressive externally audited track record, our proprietary stock rating tool - the Zacks Rank - harnesses the power of earnings estimate revisions and serves as an effective indicator of a stock's near-term price performance.

IQVIA currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Exploring Recent Trends in Stock Price

Over the preceding four weeks, the stock's value has appreciated by 4.8%, against an upturn of 2.4% in the Zacks S&P 500 composite. In parallel, the Zacks Medical sector, which counts IQVIA among its entities, has appreciated by 6.8%. Over the past three months, the company's shares have seen an increase of 20.4% versus the S&P 500's 8.2% increase. The sector overall has witnessed an increase of 13.3% over the same period.